



TriVascular Ovation Prime™


Abdominal Stent Graft System

Prof. Mangialardi, Rome



Why Another EVAR Device?

Challenges with Commonly Used Stent Grafts

Tight & Tortuous Access



Short & Hostile Proximal Necks



New Ovation Prime™ Abdominal Stent Graft


Tri-modular design

14F
OD

main body

Low-viscosity,
radiopaque,
fill polymer

High flexibility





Novel Sealing Mechanism

Ovation Prime's **polymer-filled sealing rings:**

Conform
to patient anatomy

Exclude
Aneurysms


Exert
no expansive radial force
post-procedure




Expanding EVAR – Safely

Personal experience


Thrombus




Short Angulated/Conical neck





Length: 1.9
Length: 1.9
Length: 2.23
Length: 2.4



Conical Neck





Sealing zone



Aortic dissection



1 year FU



1 year FU





1 year FU

Lowest Profile, Expanded Options

Narrow Access




Tortuous Anatomy



Control & Ease of Use

With a simple staged deployment, the suprarenal stent is accurately positioned and the integral anchors are then secured. This enhances placement accuracy while reducing the risk of migration.



OVATION^{PRIME}[™]

ABDOMINAL STENT GRAFT SYSTEM




Image size: 512 x 582
View size: 677 x 587
WL: 118 WW: 157

20117106182 (68 y , 67 y)
-- unnamed
1111
1

198

119

40


Zoom: 132% Angle: 0

Im: 2/422

JPEG2000

18/10/11 08:34:58

Made in Osirix



Ovation

Clinical and Regulatory Activities


OVATION

- CE approval 2010

OVATION PRIME

- FDA approval 2012
- CE approval 2012

Ovation - Global Clinical Program




- **1300+** Patients treated with the Ovation Stent Graft System to date
- **161** Patients treated in global pre-market trial (enrolment complete)
- Enrollment underway in 500 patient European Post Market Registry

Expanding EVAR - Safely

Anatomically Challenging Subgroup Analysis 63 Patient Subgroup

39% (63/161) of patients treated had access vessels <6mm, aortic neck length <10mm, or both.



SAFETY	0-30 Days	31-365 Days
Major Adverse Events	0% (0/63)	3.2% (2/63)
Device Related MAEs	0% (0/63)	0% (0/63)
EFFECTIVENESS	30 Days	365 Days
Freedom from Type I and III Endoleaks	100%	100%
Freedom from Migration	100%	100%
Freedom from Rupture & Conversion	100%	100%
Freedom from AAA Enlargement	100%	100%

2 MAEs @ 1 year were deaths from pre-existing conditions:



- Respiratory failure and death
- GI hemorrhage and death

Ovation's ultra low profile and advanced sealing technology produced excellent results in this anatomically challenging subgroup.



28MAY35-GR

Personal Experience



14FEB56-MF


MAY34-BC

Personal experience: 27 pts

Patients	27
Gender (Male/Female)	24/3
Mean Age (years) (Range)	72,7 (55-84)
Proximal neck diameter	23.4 (18.2-30.1)
Aneurysm	52.1 (34.5-75.0)
Iliac (R/L)	12.4/12.8 (9.3-16.6/9.2-15.7)
Access vessels (R/L)	7.5/7.7 (5.1-10/4.1-10.2)
Neck Length	≥7 mm
Delta aorta - aneurysm	54% (40-65%)
Device Time (min)	47 (30-70)


Personal experience: 27 pts

Aortic Neck



Personal experience: 27 pts

Iliac Arteries



Personal experience: 27 pts

Results

- Immediate complications
 - Bleeding 1
 - Polimer extravasation 1
(allergic reaction – no sequelae)
- Late complication
 - Type I EL 1 *
 - Branch occlusion 1 *

*** treated**

Why Another EVAR Device?

- Ovation safely and effectively addresses previously unmet clinical needs:
 - Its low profile facilitates access to the aneurysm
 - Its novel sealing technology shows good safety results
 - Ovation's IFU expands the pool of patients eligible for EVAR

Ovation is next generation EVAR technology – available TODAY and easy to use !